Dianthus Therapeutics Stock Today
| DNTH Stock | 28.09 0.26 0.93% |
Performance9 of 100
| Odds Of DistressLess than 45
|
Dianthus Therapeutics is trading at 28.09 as of the 27th of July 2024. This is a 0.93% up since the beginning of the trading day. The stock's open price was 27.83. Dianthus Therapeutics has 45 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Dianthus Therapeutics symbol was changed from MGTA on 12th of September 2023. Equity ratings for Dianthus Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of April 2024 and ending today, the 27th of July 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of September 2023 | Category Healthcare | Classification Health Care |
Dianthus Therapeutics is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 29.35 M outstanding shares of which 3.34 M shares are currently shorted by private and institutional investors with about 6.93 trading days to cover. More on Dianthus Therapeutics
Moving against Dianthus Stock
Dianthus Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Older Symbol | MGTA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| CEO and Presidentident | Marino MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dianthus Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Dianthus Therapeutics' financial leverage. It provides some insight into what part of Dianthus Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dianthus Therapeutics (DNTH) is traded on NASDAQ Exchange in USA. It is located in 7 Times Square, New York, NY, United States, 10036 and employs 53 people. Dianthus Therapeutics was previously known as Magenta Therapeutics and was traded on NASDAQ Exchange under the symbol MGTA. Dianthus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 850.25 M. Dianthus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 29.35 M outstanding shares of which 3.34 M shares are currently shorted by private and institutional investors with about 6.93 trading days to cover.
Dianthus Therapeutics generates negative cash flow from operations
Check Dianthus Therapeutics Probability Of Bankruptcy
Ownership AllocationDianthus Therapeutics holds a total of 29.35 Million outstanding shares. The majority of Dianthus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Dianthus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Dianthus Therapeutics. Please pay attention to any change in the institutional holdings of Dianthus Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Dianthus Ownership Details
Dianthus Therapeutics Historical Income Statement
Dianthus Stock Against Markets
Dianthus Therapeutics Corporate Management
| Jennifer Ruff | VP Affairs | Profile | |
| Edward Carr | Chief Officer | Profile | |
| Kristina Maximenko | Chief Officer | Profile | |
| MD MBA | Chief Officer | Profile | |
| Adam Esq | General Counsel | Profile | |
| Judson Taylor | Head Operations | Profile |
Additional Information and Resources on Investing in Dianthus Stock
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dianthus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.284 | Quarterly Revenue Growth 0.836 | Return On Assets (0.16) | Return On Equity (0.23) |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.